Part 9: What PARP inhibitors mean for the future and what to look out for
Part 9: What PARP inhibitors mean for the future and what to look out for
The case for investing in women's cancers in Asia Pacific
Nigeria solidarity support fund and the annual youth engagement campaign on HPV
Psilocybin-assisted psychotherapy for cancer-related anxiety and depression
AOH1996 treatment targeting PCNA shows promise for reoccurring solid tumours
OncoAlert round up July 28th to August 3rd, 2023
Sudan: Conflict, cancer care, and ripple effects on the region
Geriatric oncology in resource-limited settings
Gynaecological cancer: New targets and immunotherapy developments
ASCO 2023: Highlights and analysis
Dostarlimab chemo combination for primary advanced or recurrent endometrial cancer
FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer